Health
Results: 97-108 of 8078

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼

Court Authorizes Notice of Proposed Class Action Settlement for Farmers, Landscapers and Others Exposed to Weed Killers

Galderma Introduces Cetaphil AM/PM Antioxidant Serums, a New Science-Driven Defense and Recovery System for Sensitive Skin

LOTTE Biologics to Participate in DCAT Week 2026 in New York to Explore Global Partnership Opportunities

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)




